Titan Pharmaceuticals
TTNP
TTNP was delisted on the 1st of October, 2025.
40 hedge funds and large institutions have $10.9M invested in Titan Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 11 closing their positions.
24,433% more call options, than puts
Call options by funds: $736K | Put options by funds: $3K
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
0% less ownership
Funds ownership: 0% → 0% (-0%)
15% less funds holding
Funds holding: 47 → 40 (-7)
23% less capital invested
Capital invested by funds: $14.1M → $10.9M (-$3.25M)
27% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$3.14M |
| 2 |
Renaissance Technologies
New York
|
+$352K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$70.3K |
| 4 |
SG Americas Securities
New York
|
+$56.3K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$42.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$394K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$260K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$197K |
| 4 |
Russell Investments Group
London,
United Kingdom
|
-$186K |
| 5 |
AIM
Acrospire Investment Management
Chicago,
Illinois
|
-$98.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
BNP Paribas Financial Markets
Paris,
France
| $729 | – | – | – |
|
|
GCP
52
GSA Capital Partners
London,
United Kingdom
| – | -$260K | -18 | Closed |
|
|
53
Russell Investments Group
London,
United Kingdom
| – | -$186K | -14 | Closed |
|
|
54
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$197K | -14 | Closed |
|
|
VKH
55
Virtu KCG Holdings
New York
| – | -$95K | -7 | Closed |
|
56
Citigroup
New York
| – | -$70.3K | -5 | Closed |
|
|
ARTA
57
A.R.T. Advisors
New York
| – | -$58K | -4 | Closed |
|
|
BGIM
58
Brandywine Global Investment Management
Philadelphia,
Pennsylvania
| – | -$39K | -3 | Closed |
|
|
NI
59
Numeric Investors
Boston,
Massachusetts
| – | -$48K | -3 | Closed |
|
|
QCG
60
Quadrant Capital Group
Cincinnati,
Ohio
| – | -$4K | – | – |
|
TTNP Hedge Fund Activity: Q1 2017 in Review
40 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q1 2017, worth a combined $10.9M — down 23% from $14.1M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of TTNP and 8 opened new positions — a net loss of 3 holders — while 6 trimmed existing stakes and 7 added.
The largest buyer was BlackRock, opening a new position worth an estimated $3.14M. The largest seller was Morgan Stanley, cutting an estimated $394K.
- 40 institutional investors held Titan Pharmaceuticals (TTNP) as of Q1 2017, down from 47 in Q4 2016.
- Funds reported $10.9M of Titan Pharmaceuticals stock for Q1 2017, down 23% quarter-over-quarter.
- 8 funds opened new Titan Pharmaceuticals positions in Q1 2017 and 11 closed out, a net change of -3 holders.
- The largest Titan Pharmaceuticals buyer in Q1 2017 was BlackRock, an estimated $3.14M added.
- The largest Titan Pharmaceuticals seller in Q1 2017 was Morgan Stanley, an estimated $394K sold.
Based on aggregated 13F filings for Q1 2017.